Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Zimmer Biomet Holdings, Inc. has experienced a selloff alongside the healthcare sector in H2 FY'23. Despite the recent downturn, the company still represents compelling long-term value in my view. The company's Q2 numbers show growth in product revenues and strong cash flows, supporting a positive outlook for the future.

Zimmer Biomet: Knees The Key Growth Lever, Reiterate Buy On Long-Term Value

Health Care sector ETF (XLV) has underperformed the S&P 500 by 15 percentage points but has shown a modest revival in the last month. Zimmer Biomet had a solid earnings report and raised its 2023 revenue and earnings guidance, indicating potential growth. Technical risks exist, but the stock's valuation appears decent, and there is a possibility of earnings upside.

Zimmer Biomet: Guidance Raise, Better Margins In 2024 Make It A Buy

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q2 2023 Earnings Conference Call August 1, 2023 8:30 AM ET Company Participants Keri Mattox - SVP and Chief Communications & Administration Officer Bryan Hanson - Chairman, President & CEO Suketu Upadhyay - EVP & CFO Ivan Tornos - COO Conference Call Participants Travis Steed - Bank of America Merrill Lynch Richard Newitter - Truist Securities Philip Chickering - Deutsche Bank Michael Matson - Needham & Company Joshua Jennings - TD Cowen Ryan Zimmerman - BTIG Robert Marcus - JPMorgan Chase & Co. Matthew Miksic - Barclays Bank Jeffrey Johnson - Robert W. Baird & Co. Kyle Rose - Canaccord Genuity Lawrence Biegelsen - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company Jayson Bedford - Raymond James & Associates Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Second Quarter 2023 Earnings Conference Call.

Zimmer Biomet Holdings, Inc. (ZBH) Q2 2023 Earnings Call Transcript

Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.

Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised

The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.82 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.82 per share a year ago.

Zimmer Biomet (ZBH) Q2 Earnings Meet Estimates

Zimmer Biomet Holdings Inc on Tuesday raised its full-year profit forecast, anticipating demand to hold up for its medical devices following a rebound in knee and hip replacement procedures.

Medical device maker Zimmer Biomet lifts profit forecast as surgeries rebound

Second quarter net sales of $1.870 billion increased 4.9% and 6.0% on a constant currency1 basis Second quarter diluted earnings per share were $1.00; adjusted1 diluted earnings per share were $1.82 Company raises 2023 financial guidance WARSAW, Ind. , Aug. 1, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2023.

Zimmer Biomet Announces Second Quarter 2023 Financial Results

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?

Abbott Labs

Haemonetics

Stryker

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.

4 Medical Product Stocks to Buy Amid Recovering Prospects

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Insulet

Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks?

ZBH or PODD: Which Is the Better Value Stock Right Now?

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Zimmer (ZBH) Could Beat Earnings Estimates Again

WARSAW, Ind. , July 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Tuesday, August 1, 2023 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2023 Financial Results

Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.

Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches

Boston Scientific

Centene

Elevance Health Inc

HCA Healthcare

Humana

Intuitive Surgical

Surgery Partners

Smith & Nephew

Tenet Healthcare

UnitedHealth Group

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but potentially good business for surgery centers like Surgery Partners Inc. NASDAQ: SGRY and companies like Zimmer Biomet Holdings Inc. NYSE: ZBH that manufacture joint-replacement technologies.

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

Zimmer (ZBH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?

Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -8.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Zimmer (ZBH)

ResMed

Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?

ZBH vs. RMD: Which Stock Should Value Investors Buy Now?

ZBH exceeded expectations with significantly higher organic sales growth and an EPS of $1.89. I am positive about management's decision to raise full-year guidance to 6-7% ex-FX, as I believe it indicates underlying strength and improved macro dynamics.

Zimmer Biomet: Expect Growth Momentum To Continue

Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.

Here's Why Investors Should Add Zimmer Biomet (ZBH) Now

Microsoft

Roche Holding AG

Investors can find growth plays in many corners of the stock market, but  a smart play would be looking for the stocks reshaping the future. These are companies at the forefront of a burgeoning trend that look poised to run away with a large slice of the growing market share.

3 Stocks That Are Reshaping the Future

WARSAW, Ind. , May 15, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2023.

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

4 Medical Products Stocks to Capitalize on the Industry's Recovery

Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.

News for Zimmer Biomet Hlds Stock (ZBH)